{"id":"NCT00154375","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","officialTitle":"Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10","primaryCompletion":"2008-08","completion":null,"firstPosted":"2005-09-12","resultsPosted":"2011-02-02","lastUpdate":"2011-04-26"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glioblastoma Multiforme","Astrocytoma"],"interventions":[{"type":"DRUG","name":"Imatinib mesylate","otherNames":["Glivec®"]},{"type":"DRUG","name":"Hydroxyurea","otherNames":["Litalir®"]}],"arms":[{"label":"Imatinib mesylate + hydroxyurea (HU)","type":"EXPERIMENTAL"},{"label":"Hydroxyurea alone","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.","primaryOutcome":{"measure":"Percentage of Participants With Progression Free Survival (PFS) During the Study Duration","timeFrame":"6 months -1 year","effectByArm":[{"arm":"Imatinib Mesylate + Hydroxyurea (HU)","deltaMin":5.3,"sd":null},{"arm":"Hydroxyurea Alone","deltaMin":6.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":118},"commonTop":["FATIGUE","HEADACHE","THROMBOCYTOPENIA","NAUSEA","OEDEMA PERIPHERAL"]}}